CSF isoprostane levels are a biomarker of oxidative stress in multiple sclerosis
Citation Manager Formats
Make Comment
See Comments

Abstract
Objective: To investigate the potential of 8-iso-prostaglandin F2α (8-iso-PGF2α) as a biomarker for disease activity and oxidative stress in the CSF of patients with multiple sclerosis (MS).
Methods: The isoprostane 8-iso-PGF2α is an established biomarker for in vivo oxidative stress and lipid peroxidation. We measured CSF 8-isoPGF2α levels in 231 patients with MS (74 with relapsing-remitting MS, 67 with primary progressive MS, and 90 with secondary progressive MS [SPMS]) and 40 controls using a competition ELISA.
Results: We found increased CSF levels of 8-iso-PGF2α in patients with MS compared to controls, with the most striking values in a subgroup of patients with SPMS. Furthermore, the increase in 8-iso-PGF2α correlated with other parameters of lipid peroxidation as well as with a decrease in the total antioxidant status in the MS CSF samples.
Conclusions: Our study demonstrates that CSF levels of 8-iso-PGF2α may serve as a biomarker of oxidative stress in MS. Further investigation will help establish the pathologic and clinical significance of our preliminary findings.
GLOSSARY
- 8-iso-PGF2α=
- 8-iso-prostaglandin F2α;
- AAPH=
- 2,2′-azobis-2-methyl-propanimidamide dihydrochloride;
- DMF=
- dimethyl fumarate;
- EAE=
- experimental allergic encephalitis;
- EDSS=
- Expanded Disability Status Scale;
- GSSG=
- oxidized glutathione;
- IMSMP=
- International Multiple Sclerosis Management Practice;
- IRB=
- institutional review board;
- MDA=
- malondialdehyde;
- MS=
- multiple sclerosis;
- OND=
- other neurologic disorder;
- PPMS=
- primary progressive MS;
- ROS=
- reactive oxygen species;
- RRMS=
- relapsing-remitting MS;
- SOD=
- superoxide dismutase;
- SPMS=
- secondary progressive MS;
- TAS=
- total antioxidant status;
- TBARS=
- thiobarbituric acid reactive substances
Footnotes
Go to Neurology.org/nn for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing Charge was paid by the TISCH MS Research Center of NYT.
- Received January 28, 2014.
- Accepted in final form June 27, 2014.
- © 2014 American Academy of Neurology
This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Absence of systemic oxidative stress and increased CSF prostaglandin F2α in progressive MSMagda A. Lam, Ghassan J. Maghzal, Mohsen Khademi et al.Neurology: Neuroimmunology & Neuroinflammation, June 30, 2016 -
Articles
Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosisC. E. Teunissen, E. Iacobaeus, M. Khademi et al.Neurology, April 13, 2009 -
Article
A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosisAlex M. Dickens, James R. Larkin, Julian L. Griffin et al.Neurology, September 24, 2014 -
Null Hypothesis
Randomized controlled trial of N-acetylcysteine therapy for RYR1-related myopathiesJoshua J. Todd, Tokunbor A. Lawal, Jessica W. Witherspoon et al.Neurology, January 15, 2020